These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 19372841)

  • 1. An update on HIV-1 antiretroviral resistance.
    Plank RM; Kuritzkes DR
    Curr Opin HIV AIDS; 2006 Sep; 1(5):417-23. PubMed ID: 19372841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viral latency and reservoirs: relevance for mother-to-child transmission and resistance.
    Wind-Rotolo M; Doherty MC
    Curr Opin HIV AIDS; 2006 Mar; 1(2):167-73. PubMed ID: 19372803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
    Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of mother-to-child transmission, drug resistance, and implications for response to therapy.
    Lockman S
    Curr Opin HIV AIDS; 2008 Mar; 3(2):166-72. PubMed ID: 19372961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-resistant human immunodefiency virus.
    Kozal MJ
    Clin Microbiol Infect; 2009 Jan; 15 Suppl 1():69-73. PubMed ID: 19220361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug resistant mutations detected by genotypic drug resistance testing in patients failing therapy in clade C HIV-1 infected individuals from India.
    Kandathil AJ; Kannangai R; Verghese VP; Pulimood SA; Rupali P; Sridharan G; Grant P; Pillay D; Abraham OC
    Indian J Med Microbiol; 2009; 27(3):231-6. PubMed ID: 19584504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacology of HIV protease inhibitors in pregnancy.
    van der Lugt J; Colbers A; Burger D
    Curr Opin HIV AIDS; 2008 Nov; 3(6):620-6. PubMed ID: 19373033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protease inhibitor plasma concentrations in HIV antiretroviral therapy.
    Justesen US
    Dan Med Bull; 2008 Nov; 55(4):165-85. PubMed ID: 19232158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of mutations in the connection and RNase H domains of HIV-1 reverse transcriptase on drug susceptibility.
    Ehteshami M; Götte M
    AIDS Rev; 2008; 10(4):224-35. PubMed ID: 19092978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy.
    Di Giambenedetto S; Zazzi M; Corsi P; Gonnelli A; Di Pietro M; Giacometti A; Almi P; Trezzi M; Boeri E; Gianotti N; Menzo S; Del Gobbo R; Francisci D; Nerli A; Galli L; De Luca A;
    Antivir Ther; 2009; 14(3):359-69. PubMed ID: 19474470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 pol phylogenetic diversity and antiretroviral resistance mutations in treatment naïve patients from Central West Brazil.
    Cardoso LP; Queiroz BB; Stefani MM
    J Clin Virol; 2009 Oct; 46(2):134-9. PubMed ID: 19682948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
    Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG
    AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Partial treatment interruptions.
    Deeks SG; Martin JN
    Curr Opin HIV AIDS; 2007 Jan; 2(1):46-55. PubMed ID: 19372865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Broad advances in understanding HIV resistance to antiretrovirals: report on the XVII International HIV Drug Resistance Workshop.
    Mascolini M; Larder BA; Boucher CA; Richman DD; Mellors JW
    Antivir Ther; 2008; 13(8):1097-113. PubMed ID: 19195337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of selecting resistance mutations during treatment interruption.
    Martinez-Picado J; Wai Yan Tam L
    Curr Opin HIV AIDS; 2007 Jan; 2(1):6-13. PubMed ID: 19372859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viral fitness: relation to drug resistance mutations and mechanisms involved: nucleoside reverse transcriptase inhibitor mutations.
    Weber J; Henry KR; Arts EJ; Quiñones-Mateu ME
    Curr Opin HIV AIDS; 2007 Mar; 2(2):81-7. PubMed ID: 19372871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiretroviral resistance patterns and HIV-1 subtype in mother-infant pairs after the administration of combination short-course zidovudine plus single-dose nevirapine for the prevention of mother-to-child transmission of HIV.
    Chalermchockcharoenkit A; Culnane M; Chotpitayasunondh T; Vanprapa N; Leelawiwat W; Mock PA; Asavapiriyanont S; Teeraratkul A; McConnell MS; McNicholl JM; Tappero JW
    Clin Infect Dis; 2009 Jul; 49(2):299-305. PubMed ID: 19522656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance and viral subtypes: how important are the differences and why do they occur?
    Brenner BG
    Curr Opin HIV AIDS; 2007 Mar; 2(2):94-102. PubMed ID: 19372873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New developments in HIV drug resistance.
    Cane PA
    J Antimicrob Chemother; 2009 Sep; 64 Suppl 1():i37-40. PubMed ID: 19675018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Latent HIV-1 reservoirs in children: considerations for therapy.
    Persaud D
    Curr Opin HIV AIDS; 2006 Mar; 1(2):174-8. PubMed ID: 19372804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.